Physician profile
David Michael Creech
NPI 1659607406
$22,044.73
in general payments reported to CMS, 2019-2025
24 companies · $3,689 in 2025
The $3,689 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,692 · 2020: $962 · 2021: $1,881 · 2022: $2,894 · 2023: $530 · 2024: $3,397 · 2025: $3,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $1,616.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $8,688.54 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Sight Sciences, INC. | $6,978.64 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $2,222.84 | 2019-2025 | Argos, Hydrus Microstent, Wavelight Ex500 Excimer Laser |
| Allergan, INC. | $1,971.94 | 2019-2022 | |
| Ivantis, INC | $914.80 | 2019-2021 | |
| Abbvie INC. | $222.28 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Durysta |
| Ocular Therapeutix, INC. | $190.57 | 2019-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.35 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $93.64 | 2019-2021 | |
| Tepha INC | $87.05 | 2019 | |
| Dompe US, INC. | $69.41 | 2021-2025 | Oxervate |
| W. L. Gore & Associates, INC. | $59.11 | 2021 | |
| Eyepoint US, INC. | $51.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $47.56 | 2019 | |
| Rxsight INC | $47.08 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $45.07 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $36.80 | 2020 | |
| Thea Pharma INC. | $30.64 | 2025 | Iyuzeh |
| Omeros Corporation | $28.77 | 2020 | |
| Kala Pharmaceuticals, INC. | $24.41 | 2021 | |
| Bausch & Lomb Americas INC. | $23.28 | 2022 | |
| Oasis Medical, INC. | $19.77 | 2019 | |
| New World Medical,INC. | $19.67 | 2021 | |
| Rayner Intraocular Lenses Limited | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Creech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.